Resveratrol improves lipid metabolism in diabetic nephropathy rats

Front Biosci (Landmark Ed). 2020 Jun 1;25(10):1913-1924. doi: 10.2741/4885.

Abstract

Diabetic nephropathy (DN) is a major cause of chronic kidney disease characterized by insulin resistance and lipid deposition in tissues. To this end, we examined the effect of Resveratrol (RES) in streptozotocin (STZ) induced diabetic nephropathy. RES, in a dose dependent manner, decreased the insulin resistance, and improved kidney function and lipid metabolism in STZ treated rats. RES treatment increased p-AMPK alpha/AMPK alpha and p-ULK1 S777/ULK1 and the autophagy related proteins (Beclin1, LC3 II/I) and its effects on TC and improvement in insulin resistence were quenched by the inhibitor of autophagy, 3-MA. Together, these results suggest that the effect of RES in treatment of DN may involve AMPK alpha/mTOR-mediated autophagy.

MeSH terms

  • AMP-Activated Protein Kinases / metabolism
  • Animals
  • Antioxidants / pharmacology
  • Autophagy / drug effects*
  • Diabetic Nephropathies / chemically induced
  • Diabetic Nephropathies / drug therapy*
  • Diabetic Nephropathies / metabolism
  • Disease Models, Animal
  • Enzyme Activation / drug effects
  • Humans
  • Insulin Resistance
  • Lipid Metabolism / drug effects*
  • Male
  • Rats, Sprague-Dawley
  • Resveratrol / pharmacology*
  • Signal Transduction / drug effects
  • Streptozocin
  • TOR Serine-Threonine Kinases / metabolism

Substances

  • Antioxidants
  • Streptozocin
  • TOR Serine-Threonine Kinases
  • AMP-Activated Protein Kinases
  • Resveratrol